Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of benefit

This is an 8 year follow-up study looking at the long-term impact of commencing interferon beta-1a (IFNB1B) in patients presenting with a clinically isolated syndrome.

In the initial part of this placebo-controlled study, patients were randomised to receive either IFNB1b 250 μg or placebo subcutaneously every second day. After either 2 years or the diagnosis of clinically definite MS, all patients were offered open label IFNB1b treatment for a maximum period of five years. After this the patients were then enrolled in an observational extension study for up to 8.7 years.

Results demonstrated that patients who were originally randomised to receive IFNB1b had a reduced risk of developing clinically definite MS by 32.3% over the 8 year observation period, reduced annualised relapse rate and a longer median time to clinically definite MS by 1345 days. Interestingly, the difference was mainly seen during the first year of the study. Median EDSS was 1.5 and cognitive outcomes remained higher in the early treated patients.

This 8 year follow up study provides further evidence supporting the use of IFNB1b in patients with a first inflammatory event suggestive of MS.

Authors: Edan G, Kappos L
Source: J Neurol Neurosurg Psychiatry. 2013 Nov 11. doi: 10.1136/jnnp-2013-306222. [Epub ahead of print]
Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial